Alessandro Magliozzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alessandro Magliozzi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Fasano
Department of Biomedical Sciences Humanitas University Milan Italy
2 shared publications - Alessandra Nicoletti
Department “G.F. Ingrassia”, Section of Neurosciences, University of Catania, Catania, Italy
1 shared publication - Andrea Pilotto
Department of Clinical and Experimental Sciences, Neurology Unit University of Brescia Brescia Italy
1 shared publication Angela Sandri
Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences University of Verona Verona Italy
1 shared publicationAnthony E. Lang
Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic Toronto Western Hospital, University Health Network Toronto Ontario Canada
1 shared publicationBenedetta Demartini
Aldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics University of Milan Milan Italy
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (5) , e70634
Pain in Functional Motor Disorders: Clinical Correlates From the Italian Registry
Background: Pain is a frequent and disabling symptom in patients with Functional Motor Disorders (FMD), yet its clinical correlates and impact have not been characterized in large, representative cohorts. The aims of this study were to identify clinical predictors and correlates of pain intensity and interference among FMD patients. Methods: We conducted a cross‐sectional analysis within the Italian Registry of Functional Motor Disorders, including 466 adults with FMD recruited from 25 movement disorders centers. Pain was assessed using the Brief Pain Inventory (BPI), which captures pain experienced during the 24 h prior to assessment, alongside sociodemographic, clinical, and psychometric data on depression, anxiety, alexithymia, fatigue, and quality of life. Results: Pain was reported by 78.8% of participants. Fibromyalgia strongly predicted pain, whereas comorbid epilepsy was linked to reduced risk. The presence of pain was associated with a poorer self‐reported sense of physical health. Among patients with pain, higher intensity and interference were associated with younger age, Restless Legs Syndrome, Irritable Bowel Syndrome, physical trauma as a precipitating factor for FMD, anxiety, and poorer physical and mental health. Painkillers were prescribed to 41.6% of patients, yet 39.27% reported pain despite medications, and 39.48% had pain while not receiving analgesics. Conclusions: Pain is highly prevalent in FMD when assessed over the previous 24 h and is frequently reported in patients who are either not receiving analgesics or continue to experience pain despite treatment. Multiple factors influence its intensity and interference in daily life. Longitudinal studies are needed to clarify causal relationships and to inform pain management strategies.
- 18 May 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (5) , e70634
Open AccessPain in Functional Motor Disorders: Clinical Correlates From the Italian Registry
Background: Pain is a frequent and disabling symptom in patients with Functional Motor Disorders (FMD), yet its clinical correlates and impact have not been characterized in large, representative cohorts. The aims of this study were to identify clinical predictors and correlates of pain intensity and interference among FMD patients. Methods: We conducted a cross‐sectional analysis within the Italian Registry of Functional Motor Disorders, including 466 adults with FMD recruited from 25 movement disorders centers. Pain was assessed using the Brief Pain Inventory (BPI), which captures pain experienced during the 24 h prior to assessment, alongside sociodemographic, clinical, and psychometric data on depression, anxiety, alexithymia, fatigue, and quality of life. Results: Pain was reported by 78.8% of participants. Fibromyalgia strongly predicted pain, whereas comorbid epilepsy was linked to reduced risk. The presence of pain was associated with a poorer self‐reported sense of physical health. Among patients with pain, higher intensity and interference were associated with younger age, Restless Legs Syndrome, Irritable Bowel Syndrome, physical trauma as a precipitating factor for FMD, anxiety, and poorer physical and mental health. Painkillers were prescribed to 41.6% of patients, yet 39.27% reported pain despite medications, and 39.48% had pain while not receiving analgesics. Conclusions: Pain is highly prevalent in FMD when assessed over the previous 24 h and is frequently reported in patients who are either not receiving analgesics or continue to experience pain despite treatment. Multiple factors influence its intensity and interference in daily life. Longitudinal studies are needed to clarify causal relationships and to inform pain management strategies.
- Open Access
- 22 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 774-778
Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia
Background: Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches. Objectives: To assess the need for anticholinergic medications and botulinum neurotoxin injections in adult and pediatric patients at two specialized Canadian centers before and after DBS over the past 10 years. Methods: 58 patients were included analyzing data before, 6 and 12 months after DBS. Clinical assessment included the Toronto Western Spasmodic Torticollis Rating Scale and Fahn‐Marsden Dystonia Rating Scale. Anticholinergic burden was determined by the Anticholinergic Drug Scale (ADS). Results: Severity of cervical dystonia and ADS scores reduction were statistically significant after DBS. Anticholinergic medication and Botulinum Neurotoxin injections were discontinued a year after surgery in 28.8% and 72.4% of the patients, respectively. Conclusion: Simplification of anti‐dystonia treatments is another added benefit of DBS.
- 22 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 774-778
Open AccessAnticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia
Background: Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches. Objectives: To assess the need for anticholinergic medications and botulinum neurotoxin injections in adult and pediatric patients at two specialized Canadian centers before and after DBS over the past 10 years. Methods: 58 patients were included analyzing data before, 6 and 12 months after DBS. Clinical assessment included the Toronto Western Spasmodic Torticollis Rating Scale and Fahn‐Marsden Dystonia Rating Scale. Anticholinergic burden was determined by the Anticholinergic Drug Scale (ADS). Results: Severity of cervical dystonia and ADS scores reduction were statistically significant after DBS. Anticholinergic medication and Botulinum Neurotoxin injections were discontinued a year after surgery in 28.8% and 72.4% of the patients, respectively. Conclusion: Simplification of anti‐dystonia treatments is another added benefit of DBS.
- Open Access
- 19 April 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1208-1210
Levodopa‐Carbidopa Intestinal Gel in an Outpatient Setting: A 10‐Year Experience
- 19 April 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1208-1210
Open AccessLevodopa‐Carbidopa Intestinal Gel in an Outpatient Setting: A 10‐Year Experience